Innovative Tool for Assessing Atrial Fibrillation Faces Development Hurdles
A promising medical device designed to more accurately determine the severity of atrial fibrillation – an irregular heartbeat affecting millions – is still undergoing development despite showing positive results in early studies. The tool, created by YourRhythmics, a spin-off company of Maastricht UMC+, aims to help cardiologists provide the most appropriate treatment for patients with this common heart condition.
Atrial fibrillation, which causes the heart to beat irregularly and often rapidly, impacts over six million Europeans and more than 240,000 people in the Netherlands alone. Effective and timely treatment is crucial, as delays can reduce the likelihood of success and cause significant discomfort for patients. This underscores the importance of accurate diagnostic tools in cardiology.
The YourRhythmics device utilizes an advanced electrocardiogram (ECG), or heart tracing, to precisely measure the extent of atrial fibrillation. Measurements can be taken externally, using electrodes placed on the chest, or internally, using a probe placed in the esophagus near the heart. Specialized software then analyzes the data, referencing a clinical database to recommend the most suitable therapy for each patient.
According to research, this approach has demonstrated excellent results in initial trials. Yet, before the device can be made available to the public, several further steps are necessary. These include additional clinical studies in collaboration with cardiologists, ensuring the device is ready for mass production, and obtaining CE certification – a European safety standard for medical devices.
The development of the tool is being supported by subsidies from CTMM and VPZL (Valorisatie Programma Zuid-Limburg). YourRhythmics is located on the Brightlands Maastricht Health Campus, and represents the first company in which Brightlands Maastricht Health Campus has directly invested.
The company was founded as a spin-off from Maastricht UMC+. Further information about the project can be found in the 2012 CARIM Annual Report.
